Prosperity Consulting Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Prosperity Consulting Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$486K	Buy	978 +420	+75%	+$186K	0.02%	397
2026 Q1	$249K	Sell	558 -835	-60%	-$389K	0.01%	459
2025 Q4	$632K	Sell	1,393 -1,655	-54%	-$713K	0.03%	323
2025 Q3	$1.19M	Buy	3,048 +98	+3%	+$41K	0.06%	221
2025 Q2	$1.31M	Sell	2,950 -54	-2%	-$24.9K	0.1%	188
2025 Q1	$1.46M	Buy	3,004 +85	+3%	+$39.6K	0.11%	177
2024 Q4	$1.18M	Sell	2,919 -661	-18%	-$306K	0.09%	206
2024 Q3	$1.66M	Buy	3,580 +2,688	+301%	+$1.29M	0.13%	175
2024 Q2	$418K	Buy	+892	New	+$387K	0.06%	211

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Prosperity Consulting Group's VRTX Position: Q2 2026 in Review

Prosperity Consulting Group increased its Vertex Pharmaceuticals (VRTX) stake by 75% in Q2 2026, buying an estimated $186K and bringing the position to 978 shares worth $486K. The position accounts for 0.02% of the portfolio, ranked #397.

Prosperity Consulting Group first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.66M in Q3 2024. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Prosperity Consulting Group held 978 shares of Vertex Pharmaceuticals worth $486K as of Q2 2026.
Prosperity Consulting Group bought 420 Vertex Pharmaceuticals shares in Q2 2026, an estimated $186K.
Vertex Pharmaceuticals made up 0.02% of Prosperity Consulting Group's portfolio in Q2 2026, its #397 holding.
Prosperity Consulting Group first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Prosperity Consulting Group's Vertex Pharmaceuticals position peaked at $1.66M in Q3 2024.
1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Prosperity Consulting Group's 13F filing for Q2 2026, filed 13 Aug 2026.